RedHill Biopharma (RDHL) Stock Price, News & Analysis

Company Overview

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Key Stats

• Today's Range: $6.30 to $6.68
• 50-Day Range: $6.47 to $8.78
• 52-Week Range: $6.00 to $40.50
• Volume: 12,691 shs
• Average Volume: 104,650 shs
• Market Capitalization: $8.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RedHill Biopharma Stock Analysis - MarketRank™

RedHill Biopharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for RedHill Biopharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

RedHill Biopharma has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.44% of the float of RedHill Biopharma has been sold short.

Short Interest Ratio / Days to Cover

RedHill Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RedHill Biopharma has recently decreased by 17.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

RedHill Biopharma does not currently pay a dividend.

Dividend Growth

RedHill Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.44% of the float of RedHill Biopharma has been sold short.

Short Interest Ratio / Days to Cover

RedHill Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in RedHill Biopharma has recently decreased by 17.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added RedHill Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, RedHill Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.81% of the stock of RedHill Biopharma is held by insiders.

Percentage Held by Institutions

Only 7.20% of the stock of RedHill Biopharma is held by institutions.

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed this year?

RedHill Biopharma's stock was trading at $912.50 at the beginning of the year. Since then, RDHL stock has decreased by 99.3% and is now trading at $6.50.
View the best growth stocks for 2024 here.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) released its quarterly earnings data on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company had revenue of $21.61 million for the quarter, compared to the consensus estimate of $23.41 million.

When did RedHill Biopharma's stock split?

Shares of RedHill Biopharma reverse split on Tuesday, August 20th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RedHill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RDHL
• Previous Symbol: ASX:RDH
• CUSIP: N/A
• CIK: 1553846
• Web: www.redhillbio.com
• Phone: 972-3541-3131
• Fax: 972-3541-3144
• Employees: 210
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.56

Sales & Book Value

• Annual Sales: $3.71 million
• Price / Sales: 2.25
• Cash Flow: $650.00 per share
• Price / Cash Flow: 0.01
• Book Value: $40.58 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 1,281,000
• Free Float: 1,194,000
• Market Cap: $8.33 million
• Optionable: No Data
• Beta: 3.65